Temporal changes in coronary artery calcium in heart transplantation patients

Simran P Sharma1,2, Britt C J van Dijk1,2,3, Daniel Bos2,4

  • 1Department of Cardiology, Cardiovascular Institute, Thorax Center, Erasmus MC, Rotterdam, The Netherlands.

European Radiology
|December 13, 2025
PubMed

Insights

Coronary artery calcium (CAC) progression is common after heart transplantation (HT), particularly with increasing donor heart age. Monitoring CAC may help tailor cardiovascular management for HT recipients.

Area of Science:

  • Cardiology
  • Transplantation Medicine
  • Radiology

Background:

  • Coronary artery calcium (CAC) scoring assesses atherosclerotic burden.
  • Limited data exists on CAC progression and its clinical impact in heart transplant (HT) recipients.
  • Long-term follow-up of CAC in HT patients is crucial for understanding cardiovascular risk.

Purpose of the Study:

  • To evaluate the progression of coronary artery calcium (CAC) in heart transplant (HT) recipients.
  • To identify factors associated with CAC progression post-HT.
  • To provide insights into cardiovascular disease progression and risk stratification in HT patients.

Main Methods:

  • Retrospective analysis of adult HT recipients with at least 5 years post-transplant and 4 years of annual cardiac CT follow-up.
  • CAC scores assessed via non-contrast CT, categorizing patients into no progression or any increase.
  • Generalized linear mixed models and logistic regression used to analyze temporal CAC changes and associated variables.

Main Results:

  • Over half (65/116) of HT recipients showed CAC progression.
  • An average annual increase in Ln(CAC+1) of 0.4 was observed, representing a 55% relative yearly increase.
  • Donor heart age was independently associated with CAC progression; recipient age, sex, and ischemic cardiomyopathy also influenced progression rates.

Conclusions:

  • CAC progression is a common finding in HT recipients.
  • Donor heart age is the strongest predictor of CAC progression.
  • Findings suggest closer surveillance and aggressive cardiovascular management for HT patients, especially those with risk factors like younger donor age, male sex, and ischemic cardiomyopathy.
Abstract